Wealth Enhancement Advisory Services’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.2K Sell
14,422
-40,559
-74% -$57.3K ﹤0.01% 4080
2026
Q2
$85.8K Buy
54,981
+11,320
+26% +$16.5K ﹤0.01% 3833
2026
Q1
$58.5K Buy
43,661
+24,324
+126% +$43.5K ﹤0.01% 3407
2025
Q4
$40.2K Buy
19,337
+1,620
+9% +$3.11K ﹤0.01% 3541
2025
Q3
$24.8K Sell
17,717
-12,396
-41% -$16.8K ﹤0.01% 3490
2025
Q2
$48.2K Buy
30,113
+9,739
+48% +$11.2K ﹤0.01% 3230
2025
Q1
$24K Sell
20,374
-2,599
-11% -$3.99K ﹤0.01% 2907
2024
Q4
$42K Sell
22,973
-37,819
-62% -$73.8K ﹤0.01% 2882
2024
Q3
$103K Buy
60,792
+15,519
+34% +$25.5K ﹤0.01% 2554
2024
Q2
$62K Buy
45,273
+29,696
+191% +$60K ﹤0.01% 2443
2024
Q1
$58.4K Sell
15,577
-897
-5% -$5.25K ﹤0.01% 2334
2023
Q4
$162K Buy
16,474
+2,436
+17% +$19.9K ﹤0.01% 2122
2023
Q3
$117K Hold
14,038
– – ﹤0.01% 2083

Other funds holding PACB

Wealth Enhancement Advisory Services's PACB Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Pacific Biosciences (PACB) stake by 74% in Q3 2026, selling an estimated $57.3K and leaving 14,422 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

Wealth Enhancement Advisory Services first reported a position in PACB in Q3 2023 and has held it in 13 quarters since. The position peaked at $162K in Q4 2023. 205 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Wealth Enhancement Advisory Services held 14,422 shares of Pacific Biosciences worth $33.2K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 40,559 Pacific Biosciences shares in Q3 2026, an estimated $57.3K.
  • Pacific Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4080 holding.
  • Wealth Enhancement Advisory Services first reported a position in Pacific Biosciences in Q3 2023 and has held it in 13 quarters since.
  • Wealth Enhancement Advisory Services's Pacific Biosciences position peaked at $162K in Q4 2023.
  • 205 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.